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ABSTRACT
Introduction: Evaluation of patient characteristics inducing toxicity in breast radiotherapy, using simul-
taneous modeling of multiple endpoints.
Methods and Materials: In 269 early-stage breast cancer patients treated with whole-breast irradiation
(WBI) after breast-conserving surgery, toxicity was scored, based on five dichotomized endpoints. Five
logistic regression models were fitted, one for each endpoint and the effect sizes of all variables were
estimated using maximum likelihood (MLE). The MLEs are improved with James–Stein estimates (JSEs).
The method combines all the MLEs, obtained for the same variable but from different endpoints.
Misclassification errors were computed using MLE- and JSE-based prediction models. For associations,
p-values from the sum of squares of MLEs were compared with p-values from the Standardized Total
Average Toxicity (STAT) Score.
Results: With JSEs, 19 highest ranked variables were predictive of the five different endpoints.
Important variables increasing radiation-induced toxicity were chemotherapy, age, SATB2 rs2881208
SNP and nodal irradiation. Treatment position (prone position) was most protective and ranked eighth.
Overall, the misclassification errors were 45% and 34% for the MLE- and JSE-based models, respect-
ively. p-Values from the sum of squares of MLEs and p-values from STAT score led to very similar con-
clusions, except for the variables nodal irradiation and treatment position, for which STAT p-values
suggested an association with radiosensitivity, whereas p-values from the sum of squares indicated no
association. Breast volume was ranked as the most significant variable in both strategies.
Discussion: The James–Stein estimator was used for selecting variables that are predictive for multiple
toxicity endpoints. With this estimator, 19 variables were predictive for all toxicities of which four were
significantly associated with overall radiosensitivity. JSEs led to almost 25% reduction in the misclassifi-
cation error rate compared to conventional MLEs. Finally, patient characteristics that are associated
with radiosensitivity were identified without explicitly quantifying radiosensitivity.
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Introduction
One out of eight women develops breast cancer during her life-
time. Worldwide, the incidence is rising and is expected to
increase in the next decade [1]. Fortunately, the number of
breast cancer survivors is also increasing due to better aware-
ness, earlier detection and more successful treatment modal-
ities. In Belgium, the five-year relative survival rate of
female breast cancer patients is now about 90% (www.
kankerregister.org). More than 80% of patients with early-stage
(non-metastasized) breast cancer receive radiation treatment in
the adjuvant setting after surgery. Eventually, radiotherapy may
be combined with systemic therapies like hormone therapy,
chemotherapy or targeted therapy. Late radiotoxicity effects
have been well documented [2]. Skin fibrosis and pigmentation
changes, telangiectasia and cosmetic alterations have been
described [3,4]. Some of these side effects are attributed to out-
dated techniques and larger target volumes in older publica-
tions, but even with contemporary intensity-modulated
radiotherapy (IMRT) techniques, toxicity is seen in a significant
number of patients [5,6]. About 25% of patients diagnosed with
breast cancer are younger than 50 years of age. Given the high
incidence of breast cancer, the favorable survival rates, and the
often young age at diagnosis, late side effects are important to
consider when prescribing an adjuvant treatment. Inter-individ-
ual differences in the prevalence and severity of radiation-
related side effects are large. It has been shown that
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radiotherapy-related factors like total dose, dose per fraction,
irradiated volume and dose homogeneity are predictive for late
skin toxicity and cosmesis [7]. Patient and surgery-related fac-
tors like body mass index (BMI), breast volume, smoking, hyper-
tension, baseline cosmesis and post-operative infection also
play a role in developing toxicity after breast irradiation [3,8,9].
Inter-patient differences in radiation sensitivity are also assumed
to be explained by underlying genetic factors [3]. Identifying
predisposing factors can contribute to the prevention of severe
late toxicities by tailoring treatments to the individual patient.
Predictive models are also important when informing a patient
about her chance of toxicity.
Inter-individual differences in toxicity outcomes are partly
related to radiosensitivity, but also partly endpoint specific
[10–12]. Therefore, it is vital to consider multiple endpoints
in prediction models. This paper aimed to present a new
approach for modeling overall radiosensitivity and predicting
multiple toxicity endpoints and apply this approach to a
2-year toxicity data of 269 irradiated breast cancer patients.
In our study cohort, five toxicity endpoints were measured
with two goals in mind.
Firstly, prediction models were developed for all end-
points simultaneously, improving the predictions of a given
endpoint by borrowing information from other endpoints.
Secondly, predisposing factors associated with radiosensi-
tivity were identified without explicitly defining/quantifying
radiosensitivity. Radiosensitivity is never directly observed,
only multiple surrogate endpoints are measured. A technique
currently used to model associations of patient characteristics
with radiosensitivity is the Standardized Total Average
Toxicity (STAT) score [10]. The STAT score summarizes several
endpoints into a single value to mimic radiosensitivity.
However, the STAT score is an arbitrary function (standar-
dized average) of multiple endpoints with no clear clinical
meaning. Radiosensitivity is a latent outcome, and it is only
inferred through measurements of various types of radiotox-
icity. Quantifying radiosensitivity from measured toxicities
might be beyond the bounds of possibility. Our goal was to
avoid the challenging task of quantifying radiosensitivity
while identifying factors associated with it.
Material and methods
Patients
Two hundred and sixty-nine early-stage breast cancer
patients treated between 2009 and 2014 at Ghent University
Hospital with whole-breast irradiation (WBI) after breast-con-
serving surgery were included in this analysis. All patients
gave informed consent and agreed to prospective data col-
lection including digital photographs and a blood sample for
genotyping. Patients participated in one of the clinical trials
approved by the local Ethics Board and registered on www.
clinicaltrials.gov (NCT00887523, NCT01973634). Only patients
with two-year follow-up data were included.
Radiation treatment
All patients received WBI of 40.05Gy in 15 fractions; also, 32
patients were treated to the periclavicular and axillary lymph
node regions following the same fractionation scheme.
The latter patients were treated in supine position, while
patients receiving WBI without lymph node irradiation (LNI),
were either treated supine or prone. A sequential boost of
four times 2.5Gy was added, for 206 patients.
Assessment of toxicity
The grade of fibrosis and edema was scored by the respon-
sible radiation oncologist at baseline (before the start of
radiotherapy) and at every follow-up visit using the
LENT–SOMA (late effect of normal tissue–subjective, object-
ive, medical management, and analytical evaluation) toxicity
scale [13]. Pigmentation change was scored at the same time
points on a three-point scale: none, transient or permanent.
Since most patients experience fibrosis of the surgical scar,
only fibrosis outside the tumorbed was considered. Before
and two years after treatment, digital photographs of the
thorax were taken in standard conditions as described earlier
[14]. Retraction was scored on the photographs, also per the
LENT–SOMA scale. The BCCT.core (breast cancer conservation
treatment.cosmetic results) software of the INESC Porto
Breast Research Group [15], was used to assess retraction.
Photographs were taken with the arms at the level of the
hips and above the head. Based on measurements of asym-
metry, the software provides a score from 1 (excellent cos-
metic outcome) to 4 (poor cosmetic outcome) in comparison
with the non-treated breast. To assess toxicity related to
radiotherapy, the difference D, between the baseline score
and the score at two years was used. Patients with a D0
experienced no radiation-related toxicity. Patients with D1, D2
or D3, experienced an increase in toxicity of 1, 2 or 3 grades,
respectively. Telangiectasia was not included for endpoint
analysis, because of too few events.
Genotyping
Genotyping was performed for seven single nucleotide poly-
morphisms (SNPs), located in six genes. The focus was on val-
idating previously reported relationships with late skin
toxicity. The relation between rs2682585 polymorphism in
the XRCC1 gene [16] and the rs1800629 polymorphism in the
TNF gene [17], and radiation-induced toxicity was analysed.
In the genome-wide association study [18], four more poly-
morphisms were identified (SATB2: rs2881208, CCDC129:
rs882460, SLFN14: rs2840044 and CCRN4L: rs13116075).
These were also included. In addition, the rs321601 poly-
morphism near the variation mentioned above in SLFN14
was genotyped. Genomic DNA was obtained from blood
using the Puregene genomic DNA purification kit (Gentra
Systems, Minneapolis, MN, USA). Genotyping was performed
using restriction fragment length polymorphism (RFLP) analy-
ses, high-resolution melting (HRM) curve analyses and direct
sequencing. Primer sequences and restriction enzymes are
available in the Supplementary Tables S1 and S2. For repro-
ducibility control, 15% of all samples were duplicated. The
concordance rate between duplicate samples was 100%. All
genotype distributions were in Hardy–Weinberg equilibrium
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(p< .05). Only one data point for one polymorphism was
missing. Only the dominant model coding was looked at for
all SNPs. The recessive and the additive model coding (other
possible SNPs model coding) led to categories with too few
patients and unreliable statistical conclusions.
Data
The endpoints were dichotomized as follows: patients with
D0 (experiencing no radiation-related toxicity) were classified
as 0 (controls) and patients with any grade of toxicity (D1, D2
or D3) as 1 (cases). Dichotomizing between mild (grouping
D0 and D1) versus severe (grouping D2 and D3) would have
resulted in a disproportionately small group of severe toxicity
(<5% of cases). For that reason, we classified D0 as control
versus D1, D2 or D3 as cases.
Variables investigated are listed in Table 1, for the cat-
egorical and continuous variables. Missing variable values
were imputed by multiple imputations, before estimating the
effect sizes of interest.
Statistical analysis
In this section, we discuss the models, how the effect sizes
are estimated and describe an alternative approach that
leads to better predictions of individual endpoints. Moreover,
a statistical test is introduced for the identification of risk fac-
tors that are significantly associated to radiosensitivity, with-
out quantifying radiosensitivity.
With five binary endpoints, we fitted five multivariate
logistic regression models one for each endpoint, to assess
the impact of the variables on the endpoints. The standard
procedure for estimating parameters of a logistic regression
model is based on the maximum likelihood estimators
(MLEs). For prediction, individual MLEs of a given variable
can be further improved by using a combination of other
MLEs for the same variable but from different endpoints. This
seems controversial at first, and it is known as Stein’s para-
dox [19]. When there are at least three parameters analysed
simultaneously, this approach results in a lower mean
squared error (MSE), as has been demonstrated by James
and Stein [20]. This estimator will be called the James–Stein
estimator (JSE). JSE compared to MLE, may also lead to better
predictions when used in a prediction rule [21]. Five effect
sizes (MLEs) were estimated per variable, one for each of the
five endpoints. Therefore, the James–Stein estimator is dir-
ectly applicable and can be constructed from these MLEs
(see Supplementary Appendix for details). In constructing the
JSEs, the sum of squares of the MLEs for the ith variable is
computed. In particular, Si ¼
PJ
j b^
2
ij where b^ ij is the MLE of
the effect size of variable i, for the jth endpoint and J is the
total number of endpoints (J¼ 5). The JSE of the ith variable,
for the jth endpoint, is constructed using Si, as 1 J2Si
 
b^ij .
The parameter ki ¼ 1 J2Si
 
, which is called the shrinkage
parameter, drives the procedure. It is assumed that the aver-
age effect size across endpoints is zero for all variables, since
it is likely that most variables have no effect on the endpoint.
Therefore, the JSE shrinks the MLE towards zero, when Si is
approximately equal to J 2. When Si is much larger than
J 2, there is almost no shrinkage, meaning the MLEs cannot
benefit from the other endpoints. Finally, when Si is smaller
than J 2, the shrinkage parameter ki becomes negative. To
avoid negativity, the parameter is transformed to kþi (the
positive part of ki) which takes the value zero when ki is
negative. With kþi equal to zero, the effect size of variable i is
zero across all endpoints. This is a form of variable selection
(only variables with non-zero effect sizes stay in the model)
and may improve predictions.
To evaluate the predictive value of MLEs versus JSEs,
given a specific medical history, we ran one-hundred repeats
of five-folds cross-validated misclassification error rates, based
on MLEs and JSEs in a prediction rule, separately.
The sum of squares, Si, can also be used as a test statistic
(when endpoints are independent, which is the case). The
statistic, Si, has a chi-squared distribution with J¼ 5, degrees
of freedom. With five endpoints, and at a 5% significance
level, the critical value is 11.07. Sum of squares greater
than 11.07 are significantly different from zero and their
corresponding p-values can be calculated. Based on these
p-values, variables associated with radiosensitivity can be
found without explicitly quantifying radiosensitivity. The
entire modeling process is summarized in a flow diagram in
Figure 1.
In calculating the STAT score, on the other hand, the sum
of the five endpoints for each patient, its mean and variance
across patients are computed. The sum of toxicity scores for
each patient is then subtracted from the mean and divided
by the standard deviation (standardization). The STAT score
computed this way is the quantity that represents radiosensi-
tivity. A multiple linear regression model with the STAT score
as the response variable is fitted, from which p-values are
used to represent the association of radiosensitivity and
patient characteristics.
Results
Table 2 shows the MLEs and their corresponding JSEs for the
five endpoints. Ranking of the variables is based on the
shrinkage parameter ki (and its positive counterpart k
þ
i ),
which measures how far the MLEs of the ith variable are
from zero. Breast volume is the highest ranked variable.
Figure 2 gives a visual comparison between the MLEs and
JSEs. Here, the dashed line represents the distance of MLEs
from zero, i.e., the sum of squares (scaled to fit on the plot)
of effect sizes across all five endpoints. The variables were
ranked by their sum of squares, which measures how close
the effect sizes are to zero. The MLEs and their respective
JSEs are also displayed for every endpoint. Based on the
JSEs, only 19 highest ranked variables stay in the prediction
model. In descending order, most important variables
increasing radiation-induced toxicity were breast volume,
chemotherapy, age, SATB2 rs2881208 SNP and nodal irradi-
ation. The most protective variable was treatment position
(prone position), which came at the eighth rank. Sums of
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squares smaller than J 2 were observed for the clinical vari-
ables, diabetes, boost and tumor size (Table 2). Which means
the effect sizes of these variables are close to zero; conse-
quently, their shrinkage parameters (kþi ) were zero and their
MLEs were shrunken to zero for all endpoints (Table 2 and
Figure 2). This indicates that these variables were not predict-
ive of any of the endpoints and therefore omitted from the
prediction model. Boxplots (Figure 3) show the misclassifica-
tion error rates of the MLE and the JSE when used in the
prediction rule. For all the different endpoints, misclassifica-
tion error rates with JSEs are lower than those obtained via
MLEs. Overall, the misclassification error of the MLE was 45%
and that of the JSE was 34%, which is nearly 25% lower, sug-
gesting that JSE is better.
Regarding association, p-values are presented for the sum
of squares and from the model with the STAT score as end-
point (Table 2). Results of p-values from the sum of squares
versus STAT p-values show discrepancies for the variables
nodal irradiation and treatment position. For both variables,
STAT p-value suggests an association, whereas none can be
concluded based on the sum of squares. For all other varia-
bles, results were quite similar. Breast volume was ranked as
the most important variable in both techniques.
Fifteen variables with a p-value greater than 5% and a non-
zero kþi , are nevertheless retained, because inclusion of these
variables may lead to better prediction. It must be noted that
two of these 15 are only significant for STAT score analysis.
Discussion
Overall, radiosensitivity can be defined as an unknown com-
bination of several toxicity endpoints. We aimed at: (1)
searching variables associated with overall radiosensitivity
without explicitly quantifying it and (2) predictive for the
individual endpoints. We exploited James and Stein’s
approach [20], which maximizes the use of the data. That is,
it uses information from other endpoints for estimating the
effect size of a single endpoint. The sums of squares of
the MLEs was used as a test statistic to test associations of
the unknown radiosensitivity and patient characteristics.
The variables diabetes, boost irradiation and tumor size
were shrunken to zero and considered non-predictive, hence
not included in the prediction model. Modeling with the JSE
has the advantage of maintaining the information on individ-
ual endpoints, from which patients’ risk profiles can be com-
puted. Clinicians can rank patients by their risk of toxicities,
and their treatment is then tailored (e.g., adapting the doses).
Partial breast irradiation has shown to reduce toxicity, but
some studies show a higher recurrence risk. In the clinic,
patient toxicity risk profiles computed from JSEs can be used
to open discussions with patients, e.g., do you prefer whole-
breast irradiation with a high risk of toxicity or partial breast
irradiation, which is probably safe in low-risk tumors, but the
long-term outcome is unknown?
The misclassification error rate quantifies the percentage
of wrong predictions, i.e., if the model predicts a patient with
‘toxicity’ as ‘no toxicity’ and vice versa. The JSE led to smaller
misclassification errors, as presented in Figure 3. There is
always a bias-variance trade-off when parameters of a model
are estimated. The MLE is unbiased asymptotically, but may
end up with a large variance, and hence a higher rate of mis-
classification. Unlike the MLE, the JSE introduces bias which
may reduce its variance and may lead to a low misclassifica-
tion error. With the JSE, only 19 variables (the variables with
Data Logistic regression model
Maximum Like-
lihood Esti-
mates (MLE)
Sum of squares
P-values
Shrinkage parameter
λi and λ
+
i
James Stein Estimates
Predicting individua
Association to overall radiosensitivity
Estimation
l endpoints
Figure 1. Flow diagram showing the modeling steps. From the data, the model is fitted, estimation of model parameters is by maximizing the likelihood for each
endpoint. Sum of squares are computed from which association of variables to radiosensitivity can be investigated with p-values. On the other hand, for predicting
individual endpoints, the sum of squares can be transformed to shrinkage parameters, and James–Stein estimates (JSE) are computed. JSE led to better predictions
when used in the prediction rule compared to maximum likelihood estimates.
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ranks 1–19 in Table 2) were needed for prediction, thus
included in the model. In predicting different endpoints, the
JSE guaranteed 66% correct classification overall. The MLE is
making use of twenty-two variables resulted in only 55% cor-
rect classifications, which comes very close to coin flipping.
Referring to each endpoint, JSE again outperformed MLE,
with lower misclassification errors for every endpoint.
The p-values from the sum of squares are informative
for hypothesis testing/association studies. Based on these
p-values, variables associated to radiosensitivity can be found
without explicitly quantifying radiosensitivity. However, the
STAT score quantifies radiosensitivity (an unknown entity)
and goes on to investigate variables associated with it. Using
a significance level of 5%, only the first four variables from
Table 2 were significant. Larger breast volume, chemother-
apy, older age and the SATB2 rs2881208 SNP were associated
with a higher chance of developing any toxicity. These asso-
ciations have been reported before. The correlation between
breast volume and late toxicity has been seen in different
publications [3,22–25]. Since no correlation was found
between breast volume and hot spots in this dataset, the
effect cannot only be attributed to dose inhomogeneity, as
already reported by Goldsmith et al. [22]. A possible explan-
ation may be the increased presence of more adipose tissue
in large breasts. Adipocytes are known to secrete adipokines
involved in inflammation like leptin, IL-6, IL-8 or TNFa [26].
Large breast size is often seen in combination with obesity.
An increased number of macrophages and an inflammatory
signature has been shown in breast adipose tissue of obese
women compared to normal-weight women [27,28]. There is
also an association between hypertrophic adipocytes, as
often seen in obesity, and the production of pro-inflamma-
tory adipokines [26]. This chronic inflammatory state could
predispose to increased toxicity after breast irradiation. In
this dataset, there was a very strong correlation between BMI
and breast volume. If BMI was included in the model, it was
shrunk to zero, and the overall prediction performance of the
model dropped. Without breast volume in the model, BMI
became a predictive variable, but weaker than breast volume.
For this reason, BMI was left out of the model. There seems
to be a strong association between chemotherapy and tox-
icity, even if not given concomitantly with radiation as was
the case in our study. This confirms literature data [3,29,30].
There is emerging evidence that the synergistic effect of
radiotherapy and chemotherapy is explained by an effect on
the immune system. Recent investigations show that the
innate immune system is involved in the tumor response
after radiation treatment [31].
Some chemotherapeutic agents typically used in breast
cancer, like anthracyclines, taxanes and cyclophosphamides
are also capable of influencing the immune response [32]. An
increased risk of late toxicity with older age has been
reported in the boost-no boost trial [33], and in other trials
[3,29,34,35]. With increasing age, the glandular tissue is
replaced by adipose and stromal tissue, which might lead to
a higher susceptibility to radiation-related side effects as
described above. Another explanation could be the reduced
DNA repair capacity at an older age. The last significant
variable in the model, based on the sum of squares p-value,Ta
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was the rs2881208 polymorphism near SATB2. In the gen-
ome-wide association study [18], this SNP was significantly
associated with increased toxicity for all endpoints and the
STAT score. Besides these four variables, the STAT score also
detects a significant association with toxicity for nodal irradi-
ation and treatment position, even though the p-values of
these variables from the sums of squares were insignificant.
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Figure 2. Maximum likelihood estimates, MLEs, () and their corresponding James Stein estimates JSE (). Each set of MLEs and JSEs are labeled with the variable
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Figure 3. One-hundred repetition of five-folds cross validated misclassification error rates of maximum likelihood estimates (MLEs) and James–Stein estimates
(JSEs). Smaller misclassification errors are observed for the JSE compared to the MLE. Overall, the misclassification error of the MLE is 45% and that for the JSE 34%.
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having a significant STAT score p-value, no matter how
small these effect sizes are. When the nodes are irradiated,
the treated volume increases and dose inhomogeneity is
more likely to occur. These confounders may lead to sig-
nificant STAT scores. Therefore, the increase in late toxicity,
as seen in other studies [30,35], is logical. Patients treated
in a prone position are less likely to develop any of the
reported toxicities, which agrees with a randomized trial
comparing prone and supine breast radiotherapy [14]. Due
to the shape of the breast in prone position, it is much
easier to obtain homogeneous dose distributions than in
supine position. Thirteen other variables were predictive,
while their p-values were insignificant. Most of these varia-
bles were selected based on previously described associa-
tions with late toxicity after breast irradiation. The effect
sizes in our cohort were often small, and the direction of
the association was not always consistent with literature
data. Several reasons can be found. A major limitation of
our study is the small sample size. A second explanation
might be the way the endpoints were dichotomized. Due
to the very low number of serious adverse events, i.e.,
grade 2 or 3 toxicity, the groups were allocated based on
no toxicity at all (controls) and any grade of toxicity
(cases). Since grade 1 side effects are not unusual at two
years, this dichotomization may have biased the results.
We only looked at cosmetic outcomes. Given the limited
follow-up of two years, we could not evaluate data on
other, more relevant, endpoints like heart toxicity, lung
toxicity and secondary malignancies. However, we aimed at
pioneering research in the direction of modeling overall
radiosensitivity from multiple endpoints. The association of
variables with overall radiosensitivity we have modeled will
improve if data on other endpoints become available.
Conclusion
JSE is used for selecting variables that are predictive for mul-
tiple toxicity endpoints. With this estimator, 19 variables
were predictive for all toxicities, of which only four were sig-
nificantly associated with overall radiosensitivity. JSEs led to
almost 25% reduction in the misclassification error compared
to MLEs. With the sum of squares of MLEs, patient character-
istics that are associated with radiosensitivity were identified
without explicitly quantifying radiosensitivity.
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